Breaking News: F.D.A. delays action on closely watched Alzheimer’s drug

View in browser | nytimes.com   BREAKING NEWS An Alzheimer's drug that was expected to be approved soon by the F.D.A. must instead undergo more regulatory scrutiny. Friday, March 8, 2024 6:50 AM ET Eli Lilly's drug, donanemab, was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate its safety and efficacy. Read more   ADVERTISEMENT You received this email because you signed up for NYTimes.com's Breaking News Alerts. To stop receiving Breaking News Alerts, unsubscribe. To opt out of other promotional emails from the Times, manage your email preferences. Subscribe to the Times Get the NYT app Change Your Email Privacy Policy Contact Advertise California Notice The New York Times Company, 620 Eighth Avenue, New York, NY 10018